ChinaHealth

乳腺癌 在华治疗

中国于2026年3月批准了恒瑞的HER2抗体偶联药物注射用瑞康曲妥珠单抗（trastuzumab rezetecan），用于既往接受过抗HER2治疗的HER2阳性晚期乳腺癌，该药尚未获得美国FDA批准。手术、化疗和放疗是三级肿瘤医院的标准治疗方案，可通过肿瘤科或临床试验获得。
已核验最后核验

可用疗法

可用疗法在华状态在美状态信息来源
Trastuzumab rezetecan (SHR-A1811), HER2 ADC在中国已获批未获批Jiangsu Hengrui / HKEXnews

有公开项目的医院

以下为有来源的公开信息，不构成推荐。

Xuhui campus of Fudan University Shanghai Cancer Center (复旦大学附属肿瘤医院) on Dong'an Road, with the hospital name on the main tower
Shanghai复旦大学附属肿瘤医院Fudan University Shanghai Cancer CenterInternational deptReported
Name plaque at the entrance of Zhejiang Cancer Hospital, Hangzhou
Hangzhou浙江省肿瘤医院（中国科学院大学附属肿瘤医院）Zhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences)No public intl deptVerified
Peking Union Medical College Hospital, Dongdan campus
Beijing北京协和医院 国际医疗部Peking Union Medical College Hospital (PUMCH), International Medical ServicesInternational deptVerified
Beijing United Family Hospital (北京和睦家医院) building with its name sign, Jiangtai Road, Chaoyang
Beijing北京和睦家医院Beijing United Family HospitalInternational deptJCIVerified
Peking University Cancer Hospital (Beijing Cancer Hospital) (北京大学肿瘤医院) building exterior
Beijing北京大学肿瘤医院Peking University Cancer Hospital (Beijing Cancer Hospital)No public intl deptVerified
Sun Yat-sen University Cancer Center (中山大学肿瘤防治中心) building exterior
Guangzhou中山大学肿瘤防治中心Sun Yat-sen University Cancer CenterInternational deptVerified
Ruijin Hainan Hospital (瑞金医院海南医院) building with vertical 瑞金医院 signs, Boao Lecheng International Medical Tourism Pilot Zone
Hainan / Boao Lecheng上海交通大学医学院附属瑞金医院海南医院（海南博鳌研究型医院）Ruijin Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Boao Research Hospital)International deptReported
Tianjin Medical University Cancer Institute and Hospital (天津医科大学肿瘤医院) building exterior
Tianjin天津医科大学肿瘤医院（天津市肿瘤医院）Tianjin Medical University Cancer Institute and Hospital (Tianjin Cancer Hospital)International deptVerified
Cancer Hospital CAMS Shenzhen (中国医学科学院肿瘤医院深圳医院) building exterior
Shenzhen中国医学科学院肿瘤医院深圳医院Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen CenterNo public intl deptVerified
Changsha湖南省肿瘤医院（中南大学湘雅医学院附属肿瘤医院）Hunan Cancer Hospital (The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University)No public intl deptVerified
Harbin Medical University Cancer Hospital (哈尔滨医科大学附属肿瘤医院) building exterior
Harbin哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital (Heilongjiang Cancer Hospital)No public intl deptVerified

临床试验

658项研究正在中国招募（ClinicalTrials.gov，截至 2026-10-26）. 查看列表

我们只提供试验链接；是否入组由试验团队决定。据 AFP 报道，自 2026 年 5 月起中国禁止向患者收取临床研究费用。

常见问题

瑞康曲妥珠单抗在乳腺癌中的审批状态如何？

国家药品监督管理局（NMPA）于2026年3月批准该药，用于既往接受过一种或多种抗HER2药物治疗的局部晚期或转移性HER2阳性乳腺癌成人患者。HER2低表达的数据于2026年10月在ESMO会议上公布，该药尚未获得美国FDA批准。

[1] Jiangsu Hengrui / HKEXnews[2] MedPage Today

中国目前有正在招募的乳腺癌临床试验吗？

ClinicalTrials.gov网站显示，2026年10月26日中国有658项正在招募的乳腺癌研究。

[1] ClinicalTrials.gov (NLM)

信息来源

  1. Hengrui announcement: trastuzumab rezetecan approved for HER2-positive breast cancer
    Jiangsu Hengrui / HKEXnews · official · accessed 2026-10-26
    “This product is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 therapies.”
  2. Chinese Drug Shows Benefit in HER2-Low Breast Cancer
    MedPage Today · news · accessed 2026-10-26

本站仅提供信息，不构成医疗建议、诊断或治疗推荐。请咨询你的医生。紧急情况请立即拨打当地急救电话。